A wake-promoting system the brain can no longer ignore — and the drugs learning to speak its language.
Orexin is the brain's master switch for staying awake, attentive, and motivated. For two decades we have drugged it in one direction — to induce sleep. A new class of orexin‑2 receptor agonists, ORX142 among them, is now learning to turn the system up. This briefing surveys the biology, the pipeline across sponsors, and why the field is moving quickly.
Orexins — also called hypocretins — are two neuropeptides, orexin‑A and orexin‑B, cleaved from a single precursor and made by a small cluster of neurons in the lateral hypothalamus and perifornical area.1,3 Though few in number, these cells project almost everywhere in the central nervous system, wiring a single hub into the circuits that govern arousal.3,4
They act through two G‑protein‑coupled receptors. OX1R binds orexin‑A with high selectivity; OX2R binds both peptides with roughly equal affinity.3 The division of labour matters: OX2R in the histaminergic tuberomammillary nucleus is essential for maintaining wakefulness, and OX2R‑knockout animals reproduce a narcolepsy‑like phenotype while OX1R‑knockouts are largely normal.5,7
That single fact — OX2R as the wakefulness receptor — is why the newest drugs are OX2R‑selective.
Because orexin neurons receive environmental, metabolic, and emotional inputs and broadcast to the whole brain, they coordinate a set of vital functions at once.3
The system's defining role — holding waking states stable and gating transitions into REM sleep.4
Projections to the locus coeruleus and basal forebrain shape vigilance; orexin‑A can improve attention and working memory after sleep loss.16,21
Via the ventral tegmental area, orexin tunes dopaminergic reward and drive — the same axis stimulants act on.8,17
Orexin links metabolic state to arousal, coupling appetite and energy balance to being awake.3
Orexin tone interacts with stress and affective circuits; dysregulation is implicated across psychiatric disorders.17
Narcolepsy type 1 is the archetype: an autoimmune loss of orexin neurons leaves cerebrospinal orexin‑A at or below 110 pg/mL — less than a third of normal — producing excessive daytime sleepiness and cataplexy.5,16
Reduced signalling is increasingly linked to narcolepsy type 2 and idiopathic hypersomnia, where excessive sleepiness persists without complete orexin loss.18
Drug‑naïve children with ADHD show decreased serum orexin‑A, hinting that under‑arousal may contribute to attentional symptoms.6,7
Insomnia and hyperarousal reflect an over‑active wake drive — the rationale for the orexin‑blocking drugs already on the market.18
In addiction and binge‑eating disorder, orexin over‑activation in the mesolimbic dopamine system amplifies reward‑seeking; OX1R signalling in the VTA is a candidate target for compulsive craving.16,17
Orexin hyperactivity has also been tied to hypertension through heightened sympathetic tone.13
Every orexin drug either quiets the system or wakes it. The first direction is a mature, approved market. The second is the frontier.
Dual orexin receptor antagonists (DORAs) block OX1R and OX2R to reduce wake drive. Three are FDA‑approved for adult insomnia with sleep‑onset and/or maintenance problems.18
OX2R‑selective agonists restore or amplify signalling to promote wakefulness — addressing the cause of orexin‑deficient sleepiness rather than the symptom.18 None is approved yet; this is where the field is racing.
On the market today, orexin therapeutics are almost entirely blockers. The agonists — the restorative side — are all still investigational, but the leaders are close.
Most advanced in the class. Met all endpoints in the FirstLight and RadiantLight NT1 trials; under FDA priority review with a PDUFA target in Q3 2026.19
Breakthrough Therapy‑designated for NT1. Vibrance‑1 (92 patients) showed dose‑dependent gains in wakefulness; Phase 3 planned. Also studied in NT2 and idiopathic hypersomnia.20
In the adaptive CRYSTAL‑1 trial across NT1, NT2 and idiopathic hypersomnia, all doses produced statistically significant, dose‑dependent improvements in wakefulness. Registrational studies anticipated.21
A newer, potent, brain‑penetrant OX2R agonist reaching beyond sleep disorders — into neuropsychiatric territory including an exploratory ADHD study.22
Pipeline status as reported in public disclosures through mid‑2026; development stages evolve. Antagonist programmes are also in trials for psychiatric indications such as depression augmentation and binge‑eating disorder.17
ORX142 is a potent, selective, brain‑penetrant OX2R agonist being developed for sleep/wake disorders and other conditions of orexin dysregulation. Its long half‑life supports once‑daily dosing, with steady state reached around day 14.22
Animal data associate orexin agonism with seizure risk; convulsion signs occurred in dogs on a related compound at high exposures. No seizures reported clinically to date.12
Orexin agonism replaces a lost signal rather than masking the symptom — a rare thing in central‑nervous‑system medicine.
OX2R selectivity concentrates the benefit on wakefulness while sparing OX1R‑driven effects. Because the same hub touches attention, reward, mood, and metabolism, a drug that safely tunes it up has an unusually wide potential map — the reason several sponsors are moving at once.17,18
Reference numbering follows first citation in the text. Development statuses reflect public disclosures available through mid‑2026 and are subject to change.